Case Study – Page 22

Equipment qualification incomplete during requalification – regulatory deficiency case study

Understanding the Challenges of Incomplete Equipment Qualification During Requalification In the pharma manufacturing landscape, maintaining compliance with regulatory standards is paramount for ensuring product quality and safety. A recent case…

Audit trail deletion identified during data review – remediation failure analysis

Failure Analysis of Audit Trail Deletion Detected During Data Review: A Case Study In the realm of pharmaceutical manufacturing, maintaining data integrity is paramount for compliance and operational excellence. This…

Audit trail deletion identified during internal audit – 483 observation breakdown

Breaking Down an Audit Trail Deletion Identified During an Internal Audit In December 2022, during an internal audit at a mid-sized pharmaceutical manufacturing facility, an alarming issue surfaced: audit trail…

Shared analyst passwords detected during system validation – remediation failure analysis

Remediation Analysis of Shared Analyst Passwords Detected During System Validation In an increasingly regulated pharmaceutical landscape, maintaining data integrity during system validation processes is paramount. A recent compliance investigation revealed…

Backdated laboratory records during FDA inspection – remediation failure analysis

Analyzing the Remediation of Backdated Laboratory Records in FDA Inspections In the highly regulated pharmaceutical industry, data integrity is paramount for compliance and product safety. A case study focused on…

Manual result transcription without verification during FDA inspection – 483 observation breakdown

Breaking Down 483 Observations Due to Unverified Manual Result Transcription In the pharmaceutical landscape, compliance is of utmost importance. A recent FDA inspection brought to light a critical issue regarding…

Shared analyst passwords detected during FDA inspection – 483 observation breakdown

Analysis of Shared Analyst Passwords Found During FDA Inspection: A Comprehensive Case Study In the pharmaceutical industry, maintaining the integrity of data is paramount to both regulatory compliance and product…

Repeat DI lapses tolerated during internal audit – warning letter risk explained

Understanding the Risks of Repeated Data Integrity Lapses During Internal Audits In a hypothetical case study involving a mid-sized pharmaceutical manufacturer, a series of data integrity (DI) lapses were tolerated…

Shared analyst passwords detected during data review – remediation failure analysis

Investigation of Shared Analyst Passwords in Data Review: A Case Study on Remediation In a dynamic pharmaceutical manufacturing environment, maintaining data integrity is paramount, particularly when it comes to electronic…

Shared analyst passwords detected during data review – warning letter risk explained

Case Study: Addressing Shared Analyst Passwords Detected During Data Review The integrity of data within pharmaceutical manufacturing is paramount, particularly with the ongoing scrutiny from regulatory bodies like the FDA,…

Backdated laboratory records during system validation – remediation failure analysis

Analysis of Remediation Failures Related to Backdated Laboratory Records in Drug Validation Systems In the highly regulated pharmaceutical industry, ensuring data integrity during system validation is critical. This case study…

Repeat DI lapses tolerated during FDA inspection – 483 observation breakdown

Analysis of Persistent Data Integrity Lapses Observed During FDA Inspections In recent FDA inspections, several pharmaceutical manufacturing facilities have been cited for repeated lapses in data integrity (DI) practices, leading…